Pruritus News and Research

RSS
NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

VBDS secondary to nevirapine use in HIV-positive, pregnant female: Report

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Dyax launches newly enhanced product website featuring comprehensive financial assistance program

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

Phase 3 study: Tapentadol ER lowers incidence of gastrointestinal adverse events

First-of-its-kind patient, healthcare provider support program for management of HE

First-of-its-kind patient, healthcare provider support program for management of HE

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

GE Healthcare Medical Diagnostics reintroduces Optison ultrasound contrast agent for echocardiograms

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

FDA approves Purdue's Butrans Transdermal System CIII for management of chronic pain

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

AMAG, Takeda provide regulatory and clinical update for Feraheme Injection

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck challenges New York jury decision in federal FOSAMAX retrial

Japan's MHLW grants full marketing authorization to REVLIMID

Japan's MHLW grants full marketing authorization to REVLIMID

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Salix submits efficacy supplement for XIFAXAN NDA for Non-C IBS and IBS-related bloating

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO